Vireillä olevalla uudistuksella on liittymiä seulontoihin, joita tehdään myös ionisoivaa säteilyä käyttäen.

Samankaltaiset tiedostot
Tähtäimessä vaikuttavuus turvallisesti. - HTA terveydenhuollon laitteiden näkökulmasta. Tom Ståhlberg Johtaja, Viranomaisasiat

Kliininen auditoinnin

TIEKE Verkottaja Service Tools for electronic data interchange utilizers. Heikki Laaksamo

Innovative and responsible public procurement Urban Agenda kumppanuusryhmä. public-procurement

EUROOPAN PARLAMENTTI

On instrument costs in decentralized macroeconomic decision making (Helsingin Kauppakorkeakoulun julkaisuja ; D-31)

Capacity Utilization

Tarua vai totta: sähkön vähittäismarkkina ei toimi? Satu Viljainen Professori, sähkömarkkinat

RANTALA SARI: Sairaanhoitajan eettisten ohjeiden tunnettavuus ja niiden käyttö hoitotyön tukena sisätautien vuodeosastolla

EU:n lääketutkimusasetus ja eettiset toimikunnat Suomessa Mika Scheinin

Infrastruktuurin asemoituminen kansalliseen ja kansainväliseen kenttään Outi Ala-Honkola Tiedeasiantuntija

This notice in TED website:

On instrument costs in decentralized macroeconomic decision making (Helsingin Kauppakorkeakoulun julkaisuja ; D-31)

Talousarvion valvontavaliokunta LAUSUNTOLUONNOS. perussopimus-, työjärjestys- ja toimielinasioiden valiokunnalle

Sisävesidirektiivin soveltamisala poikkeussäännökset. Versio: puheenjohtajan ehdotus , neuvoston asiakirja 8780/16.

Smart specialisation for regions and international collaboration Smart Pilots Seminar

Hankkeen toiminnot työsuunnitelman laatiminen

Viite Komission kirje Asia Suomen vastaus komissiolle kansallisten romanistrategioiden toimeenpanon edistymisestä

ISSRC Information Systems Security Research Center. University of Oulu, Department of Information Processing Science T.Wiander, M.

Kaivostoiminnan eri vaiheiden kumulatiivisten vaikutusten huomioimisen kehittäminen suomalaisessa luonnonsuojelulainsäädännössä

NAO- ja ENO-osaamisohjelmien loppuunsaattaminen ajatuksia ja visioita

2017/S Contract notice. Supplies

Constructive Alignment in Specialisation Studies in Industrial Pharmacy in Finland

Efficiency change over time

The role of 3dr sector in rural -community based- tourism - potentials, challenges

A new model of regional development work in habilitation of children - Good habilitation in functional networks

Rotarypiiri 1420 Piiriapurahoista myönnettävät stipendit

CAT-IPs Focus group 3 on incentives for Academia, Hospitals and Charities. Objectives and outcome of the Focus group meeting in 2011

Supplies

16. Allocation Models

Tork Paperipyyhe. etu. tuotteen ominaisuudet. kuvaus. Väri: Valkoinen Malli: Vetopyyhe

1. SIT. The handler and dog stop with the dog sitting at heel. When the dog is sitting, the handler cues the dog to heel forward.

Hankintailmoitus: Pohjois-Savon sairaanhoitopiirin kuntayhtymä/kiinteistöyksikkö : Puijon sairaalan Pääaula-alueen uudistus, Sähköurakka

7. Product-line architectures

7562/15 rir/sj/akv 1 DGG 2B

Työsuojelurahaston Tutkimus tutuksi - PalveluPulssi Peter Michelsson Wallstreet Asset Management Oy

7.4 Variability management

Network to Get Work. Tehtäviä opiskelijoille Assignments for students.

Suomen JVT- ja Kuivausliikkeiden Liitto ry The Association of Finnish Damage Restoration Companies

AKKREDITOITU TESTAUSLABORATORIO ACCREDITED TESTING LABORATORY

EU FP7 EURATOM vuoden 2011 työohjelman valmistelu, mitä tiedetää. ään n? Reaktoriturvallisuus

National Building Code of Finland, Part D1, Building Water Supply and Sewerage Systems, Regulations and guidelines 2007

Supplies

Keskeisiä näkökulmia RCE-verkoston rakentamisessa Central viewpoints to consider when constructing RCE

Organisaation kokonaissuorituskyvyn arviointi

Aiming at safe performance in traffic. Vastuullinen liikenne. Rohkeasti yhdessä.

NON-DESTRUCTIVE TESTING OF MECHANICAL EQUIPMENT FOR NUCLEAR PLANTS OF OLKILUOTO

Toimitusketjun vastuullisuus ja riskien hallinta

MUSEOT KULTTUURIPALVELUINA

Curriculum. Gym card

Hankkeiden vaikuttavuus: Työkaluja hankesuunnittelun tueksi

Teacher's Professional Role in the Finnish Education System Katriina Maaranen Ph.D. Faculty of Educational Sciences University of Helsinki, Finland

Alternative DEA Models

Olet vastuussa osaamisestasi

Other approaches to restrict multipliers

HMG-CoA Reductase Inhibitors and safety the risk of new onset diabetes/impaired glucose metabolism

ProAgria. Opportunities For Success

* for more information. Sakari Nurmela

EU:n puiteohjelman eettisen ennakkoarvioinnin peruste, tavoite ja käytäntö

Windows Phone. Module Descriptions. Opiframe Oy puh Espoo

Benchmarking Controlled Trial - a novel concept covering all observational effectiveness studies

Returns to Scale II. S ysteemianalyysin. Laboratorio. Esitelmä 8 Timo Salminen. Teknillinen korkeakoulu

Tuloksia ja kokemuksia / results and experiences

LX 70. Ominaisuuksien mittaustulokset 1-kerroksinen 2-kerroksinen. Fyysiset ominaisuudet, nimellisarvot. Kalvon ominaisuudet

Skene. Games Refueled. Muokkaa perustyyl. for Health, Kuopio

Results on the new polydrug use questions in the Finnish TDI data

On instrument costs in decentralized macroeconomic decision making (Helsingin Kauppakorkeakoulun julkaisuja ; D-31)

Potilaan säteilyaltistuksen vertailutasot aikuisten tavanomaisissa röntgentutkimuksissa

Pricing policy: The Finnish experience

Suomen 2011 osallistumiskriteerit

LUONNOS RT EN AGREEMENT ON BUILDING WORKS 1 THE PARTIES. May (10)

Tutkimuslääkkeiden GMP. Fimea Pirjo Hänninen

ETELÄESPLANADI HELSINKI

Alkuperätakuun aamupäivä Kaija Niskala. Uusiutuvan energian direktiivin RED II muutosehdotukset

Equality of treatment Public Services

Vuosi Jukka Rinnevaara Toimitusjohtaja

Green Growth Sessio - Millaisilla kansainvälistymismalleilla kasvumarkkinoille?

Julkaisun laji Opinnäytetyö. Sivumäärä 43

Guideline on Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues

Land-Use Model for the Helsinki Metropolitan Area

ECSEL - Electronic Components and Systems for European Leadership

Information on preparing Presentation

Oikeusministeriö E-KIRJELMÄ OM LAVO Riitta Hämäläinen VASTAANOTTAJA Eduskunta Suuri valiokunta EU/2006/0587

Choose Finland-Helsinki Valitse Finland-Helsinki

Uusi jätelaki kuntayhtiön kannalta

Sosiaali- ja terveydenhuollon kehittämisestä

Helsinki Metropolitan Area Council

Technische Daten Technical data Tekniset tiedot Hawker perfect plus

AKKREDITOITU TESTAUSLABORATORIO ACCREDITED TESTING LABORATORY VERKOTAN OY VERKOTAN LTD.

Plant protection of cereals current situation

LYTH-CONS CONSISTENCY TRANSMITTER

Association Regulation

The CCR Model and Production Correspondence

Kliininen päättely. Thomsonin mallin mukaisen yhteistyön näkyminen fysioterapiatilanteessa

Vastuullinen liikenne. Yhteinen asia.

C++11 seminaari, kevät Johannes Koskinen

Markkinatoimikunta Suomi Norja siirtoyhteys

Säädösuudistus 2013/59/Euratom

Oikeutusarvioinnin menettelyt erilaisissa tilanteissa STUKin säteilyturvallisuuspäivät, Jyväskylä Ritva Bly

Tutkimuksen huippuyksiköt. Maiju Gyran tiedeasiantuntija

Transkriptio:

Säteilyturvakeskus Lausunto 1(1) Haataja, Ville 16.6.2017 Julkinen LAUSUNTO Viite: STM037:00/2017 Sosiaali- ja terveysministeriö on 5.5.2017 pyytänyt lausuntoa luonnoksesta valtioneuvoston asetukseksi erikoissairaanhoidon työnjaosta ja eräiden tehtävien keskittämisestä. Säteilyturvakeskus esittää lausuntonaan seuraavaa. Vireillä olevalla uudistuksella on liittymiä seulontoihin, joita tehdään myös ionisoivaa säteilyä käyttäen. Seulontaan liittyvä toiminta on tärkeää organisoida tavalla, joka tukee seulonnassa käytettävien terveydenhuollon menettelyjen ja säteilylain (592/1991) 2 :ssä tarkoitetun oikeutusperiaatteen perusteellista arviointia. Oikeutusperiaatteen mukaan toiminnalla saavutettavan hyödyn on oltava suurempi kuin siitä aiheutuva haitta. Pohjoismaiset säteilyturvallisuusviranomaiset ovat käsitelleet oikeutusarviointia ja terveydenhuollon menetelmien arviointia 24.10.2016 päivätyssä lausumassaan (liitteenä). Perusteellisen arvioinnin toteutumista voidaan nähdä edistettävän asetusluonnoksen 4 :n 9 kohdan säännöksellä, jonka mukaan yliopistollista sairaalaa ylläpitävän sairaanhoitopiirin on huolehdittava terveydenhuollon menetelmien arvioinnista valtakunnallisessa yhteistyössä. Pohjois-Pohjanmaan sairaanhoitopiirille annettaisiin 3 :n 6 kohdan mukaan terveydenhuollon menetelmien arviointia sairaanhoitopiireissä koskevat koordinaatiotehtävät. Arvioinnin kannalta merkittävää on myös se, että Helsingin ja Uudenmaan sairaanhoitopiirille annettaisiin 3 :n 1 kohdan mukaan syövän ehkäisyn, diagnostiikan, hoidon ja kuntoutuksen valtakunnallista suunnittelua ja toiminnan yhteensovittamista koskevat tehtävät, joita hoidettaessa on huolehdittava toimintojen tutkimuksellisesta pohjasta. Maakunta- ja sote-uudistuksen tullessa voimaan seulontojen järjestämisvastuu siirtyy kunnilta maakunnille. Asetusluonnoksen perustelujen mukaan tässä yhteydessä tarkistetaan myös seulonnoista annettua valtioneuvoston asetusta (339/2011). Seulontojen kokonaisprosessien laadunvarmistusta tulee perustelujen mukaan tehostaa yhdessä Terveyden ja hyvinvoinnin laitoksen kanssa. Seulonta-asetuksen 3 :n mukaan seulonnan järjestäjän on muun kuin valtakunnallisen seulonta ohjelman osalta esitettävä säteilylle altistavaa seulontaa koskeva arvio Terveyden ja hyvinvoinnin laitoksen tarkastettavaksi ennen seulonnan aloittamista. Terveyden ja hyvinvoinnin laitos antaa tästä kolmen kuukauden kuluessa järjestäjälle lausunnon siitä, onko seulonnalla saavutettava kansanterveydellinen hyöty suurempi kuin siitä aiheutuva kokonaishaitta. Säteilyturvakeskus pitää tärkeänä, että jatkossakin turvataan menettely, jossa säteilytoimintaa harjoittavista toimijoista erillinen ja riippumaton viranomainen arvioi säteilylle altistavalla terveydenhoidon menetelmällä saavutettavan kansanterveydellisen kokonaishyödyn ja että arvioinnissa otetaan huomioon myös säteilyturvallisuusnäkökohdat.

>STUK Asiakirja on laadittu ja allekirjoitettu sähköisesti. Dokumentet har uppsatt och undertecknats elektroniskt. This document has been digitally prepared and signed. Johtaja Annakaisa Koskinen Ratkaistu 16.6.2017 Lakimies Ville Haataja Esitelty 16.6.2017 STUK SÄTEILYTURVAKESKUS Osoite / Address» Laippatie 4, 00880 Helsinki STRÄLSÄKERHETSCENTRALEN Postiosoite / Postal address PL / P.O.Box 14, FI-00881 Helsinki, FINLAND RADIATION AND NUCLEAR SAFETY AUTHORITY Puh. / Tel. (09) 759 881, +358 9 759 881 Fax (09) 759 88 500, +358 9 759 88 500 www.stuk.fi

i Sträl säkerhets myndigheten 5UNDHEDSSTYRELSEN STRÄLEBESKYTTELSE Statens strälevern Norwegian Radiation Proiection Authority GEISLAVARNIR R1KISINS ICELANDIC RADIATION SAFETV AUTHORITY &STUK Nordic position statement on justification of new types of practices involving medical exposure The Nordic Radiation Protection co-operation The new European directive on radiation protection reinforces the requirements for justification of medical exposures. The Nordic radiation protection authorities recommend the integration of level 2 justification into established methods for assessments of new health technologies as one approach to strengthen the justification process. A Nordic cooperation has been established between the national radiation protection authorities within the Nordic Group on Medical Applications (NGMA) to support and harmonize the national implementation of this recommendation and to strengthen the dialogue with other relevant national bodies, preferably competent health technology assessment (HTA) bodies. Justification is one of the core principles in the international framework for radiation protection provided by the International Commission on Radiological Protection (ICRP) [1,2]. Justification of medical exposure is done by weighing the radiation detriments against clinical benefit and should he performed at three levels: Level 1 of the justification process considers the use of radiation in medicine in general. Level 2 of the justification process considers the use of a specific procedure or method involving medical exposure with the aim to ensure that the procedure increases the diagnostic or therapeutic outcome of the exposed individual before the procedure is taken into general clinical practice. Level 3 of the justification process considers the individual diagnostic or therapeutic outcome from a particular procedure taking into account the characteristics of the individual exposed. Level 1 justification is taken for granted within medical exposure, since the net benefit is identified to outweigh the radiation detriment in general. However, levels 2 and 3 of the justification process are crucial within medical exposure and have been part of the European and international radiation protection regulatory framework for many years [3, 4], The establishment of comprehensive national Systems for level 2 justification is complex and systems are still under development in many countries including the Nordic countries. The importance of level 2 justification has reiterated in the new European and international Basic Safety Standards (BSS) [5, 6] and the European Commission has identified the need for increased awareness of the challenges of level 2 justification and suggests that Member State cooperate on this issue [7]. Different approaches have been under consideration for establishment of a national formal system for level 2 justification. The Nordic radiation protection authorities recommend integration of level 2 justification into assessments of new health technologies. Assessments may be based on the health technology assessment (HTA) terminology, which is described in Appendix B. Date of acceptance: 24.10.2016

Integration of level 2 justification into the assessment process will be an efficient approach, since the risk-benefit evaluation to be performed in the level 2 justification process is similar to the total risk-benefit evaluation already performed in for example HTAs. This approach will ensure that the radiation detriment is evaluated as part of the total risk associated with the new practice and that level 2 justification constitute one of many aspects to be covered by the assessment. The Nordic radiation protection authorities have identified a closer relationship betvveen level 2 justification and ETA and other similar methods as a valuable tool for continued development of justification of medical procedures and will promote the adoption of such approaches in an effort to facilitate the harmonization of the implementation of level 2 justification. The implementation of level 2 justification in existing Systems and processes can be challenging and will not ahvays be straightfonvard. It is important to include experts with sufficient competence in radiation protection to ensure that the radiation risk is properly addressed in the assessments. A close cooperation between the national radiation protection authority and other competent bodies, e.g. competent, independent ETA bodies, is encouraged to succeed with this approach. It is unrealistic for any country to have enough resources to perform comprehensive assessments for ali new health technologies, and it is therefore necessary for each country to establish clear criteria for when assessments should be performed and at what level. As a first approach, a comprehensive assessment (e.g. Full-ETA) should be carried out for methods involving high level of exposure, new screening methods or if the method involves significant occupational or public exposure. Minor modifications of already established practises should be justified at a local level (e.g. by Mini-ETA) if necessary. To make the best use of available resources, the evaluation of the evidence (safety and clinical effect) should preferably be carried out through European or international cooperation while the evaluation of the consequences associated with the decision to implement the method should be made nationally. By promoting the above approach for the implementation of level 2 justification among the Nordic and European countries, already established networks, e.g. the European ETA network, can facilitate European cooperation and harmonization of the implementation of level 2 justification at a European level as already stressed by the EC [7]. References [1] ICRP, 2007. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Annals of the ICRP 2007; 37(2-4). [2] ICRP, 2007. Radiological protection in medicine. ICRP publication 105. Annals of the ICRP 2007; 37(6). [3] European Commission, 1997. Council Directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure, and repealing Directive 84/466/Euratom. Official Journal L 180, 09.07.1997: 22-27. [4] IAEA, 1996. International basic safety standards for protection against ionizing radiation and the safety of radiation sources. IAEA safety series 115. Vienna: International Atomic Energy Agency, 1996. [5] European Commission, 2014. Council Directive 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionizing radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Official Journal of the European Union L 13, 17.1.2014. [6] IAEA, FAO, ILO, et ah, 2014. Radiation protection and safety of radiation sources: international basic safety standards. IAEA safety standards series, GSR part 3. Vienna: International Atomic Energy Agency, 2014. [7] European Commission, 2015. Council conclusions on Justification of medical imaging involving exposure to ionizing radiation. Brussels, 3 December 2015. Council of the European Union 14617/15. http://www.sante.public.lu/ff/politique-sante/presidence-2015/radioprotection/ccsmedical-imaging-en.pdf ('21.10.2016') Page 2 of 4

Appendices Appendix A - New European Basic Safety Standard for Radiation Protection The European Council has issued a new European directive laying down basic safety standards for protection against the dangers arising from exposure to ionizing radiation [1]. As mentioned earlier, this directive has reiterated the requirements for Member States to develop a regulatory framework that provides for level 2 justification in general and especially for medical exposure. Article 19 - Justification ofpractises 1 in general]: 1. Member States shall ensure that new classes or types of practices resulting in exposure to ionising radiation are justified before being adopted. 2. Member States shall consider a review of existing classes or types ofpractices with regard to their justification whenever there is new and important evidence about their efficacy or potential consequences or new and important information about other techniques and technologies. 4. Practices involving medical exposure shall be justified both as a class or type of practice, taking into account medical and' where relevant, associated occupational and public exposures, and at the level of each individual medical exposure as specified in Article 55. Article 55 -Justification respeciallv for medical exposures]: 1. Medical exposure shall show a sufficient net benefit, weighing the total potential diagnostic or therapeutic benefits it produces, including the direct benefits to health of an individual and the benefits to Society, against the individual detriment that the exposure might cause, taking into account the efficacy, benefits and risks of available alternative techniques having the same objective but involving no or less exposure to ionising radiation. 2. Member States shall ensure that the principle defined in paragraph 1 is applied and in particular that: (a) new types of practices involving medical exposure are justified in advance before being generally adopted. The directive has to be implemented in national legislation before 6th of February 2018 and ali the European Member States are now working with the transposition of this directive into national legislation and regulatory framework for radiation protection. Denmark, Finland and Sweden are ali EU-countries and obliged to implement the directive, while Norway and Iceland are not. However, both Norway and Iceland have decided to, in a graded approach, to harmonize their national legislation and regulatory framework with this new EU-BSS. The European cooperation between the Fleads of the European Radiological Protection Competent Authorities (HERCA) is currently working to identify a common understanding of the requirements regarding level 2 justification in the new EU-BSS and to assist Member States in their work with the transposition of the directive into national legislation [13]. Appendix B - Health technology assessments (HTA) terminology Health technology assessment is a systematic evaluation of available knowledge on safety and clinical effect of the method combined with an evaluation of cost-effectiveness as well as ethical, social, organizational and juridical aspects. The main purpose of a HTA is to serve as a tool for decision-making in the introduction of new health technologies and practices by ensuring that they are safe, cost-effective and associated with evidence based clinical effect. It is therefore important to continue the work to establish a national formal link between HTA and the decisionmaking process in health care. Further, it is crucial that this decision-making process is transparent, unbiased and based on proper stakeholder involvement. Page 3 of 4

National approaches differ, but in most countries different levels of HTA exist, often referred to as Full-, Rapid- and Mini-HTA: A Full-HTA is a comprehensive assessment of a Health technology covering ali aspects. A Rapid-HTA is a more limited analysis performed within a shorter timeframe and focusing mostly on the safety and effectiveness of the technology. Mini-HTA is a very limited assessment performed by the hospitals, reflecting the local aspects of implementing new technologies. An HTA is also the tool used for an evidence based decision to phase-out practices that is no longer clinically effective or cost-effective. It is important to distinguish between health technology regulations (HTR) and HTAs. While HTR form a regulatory process covering ali medical devices and drugs, HTA is mainly reserved for the more complex problems. Several Nordic countries have national or regional competent HTA bodies which are members of the European HTA platform, EUnetHTA [3], This platform is responsible for European cooperation on HTA production and has developed different tools for HTAs, including a core model for the production of HTAs. It is also the platform used to conduct European Joint Actions on HTAs, founded by the EC, like EUnetHTA Joint Action 1, 2 and 3 [4, 5, 6]. In addition, the European Commission established a European HTA Network (HTAN) in 2013 [7], References [1] European Commission, 2014. Council Directive 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionizing radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Official Journal of the European Union L 13, 17.1.2014. [2] Heads of European Radiological Protection Competent Authorities, http://www.herca.org/ (21.10.2016) [3] European Network for Health Technology Assessment. http://www.eunethta.eu/ (21.10.2016) [4] EUnetHTA Joint Action 1. http://www.eunethta.eu/activities/eunethta-ioint-action-2010-12/eunethta-ioint-action-2010-12 (21.10.2016) [5] EUnetHTA Joint Action 2. http://www.eunethta.eu/activities/eunethta%20joint%20action%202%20t2012-l 5)/eunethtaioint-action-2-2012-2015 121.10.20161 [6] EUnetHTA Joint Action 3. http://www.eunethta.eu/news/eunethta-ioint-action-3-formalpreparatorv-work-starting (21.10.2016) [7] Health Technology Assessment Network. http://ec.europa.eu/health/technology assessment/policv/network/index en.htm (21.10.2016) Page 4 of 4